Loading...

RVL Pharmaceuticals plc

RVLP•NASDAQ
Healthcare
Biotechnology
$0.03
$-0.01(-32.05%)

RVL Pharmaceuticals plc (RVLP) Stock Overview

Explore RVL Pharmaceuticals plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.2/100

Key Financials

Market Cap3.1M
P/E Ratio-0.05
EPS (TTM)$-0.71
ROE-0.81%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.09

RVLP Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of RVL Pharmaceuticals plc (RVLP) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.09.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.05 and a market capitalization of 3.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for RVLPStats details for RVLP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for RVLPAnalyst Recommendations details for RVLP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

CEO

Brian A. Markison

Employees

125

Headquarters

400 Crossing Boulevard, Bridgewater, NJ

Founded

2018

Frequently Asked Questions

;